AnaptysBio Inc (NASDAQ:ANAB) saw a significant increase in short interest in the month of December. As of December 29th, there was short interest totalling 1,387,012 shares, an increase of 40.3% from the December 15th total of 988,390 shares. Approximately 9.8% of the company’s stock are short sold. Based on an average daily trading volume, of 280,607 shares, the days-to-cover ratio is presently 4.9 days.

AnaptysBio (NASDAQ:ANAB) opened at $110.45 on Friday. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $116.67. The stock has a market cap of $2,570.00 and a price-to-earnings ratio of -73.15.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. sell-side analysts anticipate that AnaptysBio will post -1.72 EPS for the current fiscal year.

ANAB has been the topic of several research reports. JMP Securities lifted their price objective on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Credit Suisse Group lifted their price objective on shares of AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Royal Bank of Canada lifted their price objective on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Robert W. Baird set a $69.00 price objective on shares of AnaptysBio and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. AnaptysBio currently has a consensus rating of “Buy” and an average price target of $88.00.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANAB. Evercore Wealth Management LLC purchased a new position in AnaptysBio in the third quarter worth $100,000. Legal & General Group Plc grew its holdings in AnaptysBio by 160.8% in the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 1,951 shares during the last quarter. DAFNA Capital Management LLC grew its holdings in AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 1,000 shares during the last quarter. New York State Common Retirement Fund purchased a new position in AnaptysBio in the second quarter worth $168,000. Finally, Nationwide Fund Advisors grew its holdings in AnaptysBio by 89.5% in the third quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 2,776 shares during the last quarter. 75.48% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “AnaptysBio Inc (ANAB) Sees Significant Increase in Short Interest” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2018/01/19/anaptysbio-inc-anab-sees-significant-increase-in-short-interest.html.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.